In the GISSI trial, 11,712 patients with acute myocardial infarction were randomized to receive either standard care or standard care with 1.5 million units streptokinase intravenously. A highly significant reduction in mortality during hospitalization in streptokinase-treated patients was observed. The mortality at 1 year was determined in 98.3% of the patients who had been originally randomized; the 1 year mortality of patients discharged alive was similar in those patients treated with streptokinase and those who were not; that is, the beneficial Over the last few years very large scale clinical trials have been recognized as a uniquely powerful tool for assessing the effectiveness of selected interventions on the natural history of diseases whose origin and prognosis are known to be multifactorial. Because of their complexity these clinical conditions are, in fact, expected to be only partially modified by any single treatment. The beneficial effects, if they exist, are likely to be detected in only a small fraction of patients by employing end points that may differ in their clinical relevance and their duration. The large population that must be recruited to test the statistical and clinical significance of the effect of the intervention constitutes a formidable organizational challenge. At the same time, a large population has the advantage of allowing the generation of testable hypotheses in subgroups of patients.
The large scale study of the treatment of acute myocardial infarction with streptokinase, conducted by the Gruppo Italiano per la Sperimentazione della Streptochinasi nellInfarto Miocardico (G1SSI), is presented here as an example of a trial providing answers to an important question in
Italy,
IDl9g7 by the AmericanCollege of Cardiology effects of streptokinase treatment on survival that were observed in the hospital phase of the study persisted unchanged and with comparable statistical significance for 1 year. However, a higher incidence of reinfarction occurred in the treated versus the control groups both during the hospital phase and at the 6 month follow-up. Streptokinase treatment had no detectable effect in patients with a history of previous infarction.
( J Am Coli Cardiol1987; 10:33B-98) contemporary cardiology, while simultaneously generating complementary information that may be useful for the understanding of acute myocardial infarction and for evaluating and planning additional research. We summarize here the short-term findings and present a preliminary analysis of the intermediate and long-term results of the trial.
GISSI Study Protocol
The design and method of GISSI have been described in detail previously (1). For the purpose of this presentation it is useful to reemphasize some of the features of the study protocol.
An open design was adopted, with no constraints on the participating clinicians other than central randomization of the eligible patients to either a streptokinase or a control (no streptokinase) group. The patients entered into the trial were managed according to the routine practice of eaeh individual clinical setting, the only recommendation being that the same attitude be adopted for the treated and control groups. The well balanced distribution of the use of cardiovascular drugs in the two groups that was found both in the hospital phase and at the planned 6 month follow-up documents the highly satisfactory compliance with the protocol by the investigators (Table 1) , Accordingly, it appears appropriate to discuss the principal and secondary findings of the trial as depending solely on the fact that patients were C '" control group; SK = streptokinase-treated group.
or were not treated with J.5 million units of streptokinase infused over 60 minutes.
The GISSI population can further be seen as a highly representative sample of patients with acute myocardial infarction admitted routinely to a general coronary care unit, because only about go/(; of the eligible patients were not randomized for reasons not anticipated in the protocol. Data were analyzed and are presented according to the intention to treat principle, even though only 4% of the patients did not receive the full assigned treatment because of intervening complications. Finally. although a detailed follow -up record at 6 months was available for only 72.4% of the recruited patients (82.2% of those discharged alive). the 
Results of the GISSI Trial
Mortality. Table 2 summarizes the results of the trial in relation to the primary end point of in-hospital mortality. the relative risk estimates have been divided into planned (prospective) and data-derived (post hoc) findings, to comply with the traditional rule that stratifications may give information of varying reliability according to whether or not they were linked prospectively to the hypothesis to be tested.
Patients with complete data I 1.712 (9Y. I~~of randomized) ROVELLI n AI.. The overall results of the study population 4 ter the I yearjollow-up are presen ted ill Figure 2 . which documents that the beneficial effect of streptokinase treatment persists substantially unchanged and with comparable statistical significance as in the hospital phase (p = 0.006). The I year mortality of the patients discharged alive from the hospital is presented in Table 3 , which shows a striking similarity between the treated and the control COh0l1S with respect to life expectancy.
GISSI EARLY RESI:LTS AND LATE fOI.I.O W-UP
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Clinical cardiac and cerebral events. The outcome of the GISSI population with respect to clinically assessed cardiac and cerebral events for the hospital phase and at the 6 month follow-up is shown in Table 4 . Three clinical end points showed important differences between the treated and control cohorts in the acute hospital phase (reinfarction, left ventricular failure and pericarditis), but only the reinlarction rate revealed a persistent difference at 6 months. The low rate of coronary bypass surgery and coronary angioplasty (well balanced in the two cohorts) excludes any specific influence of the procedures in determining the outcome. Stroke appears to remain a treatment-independent event in the follow-up period.
Discussion
Effect on early mortality. The principal conclusion derived from the final results of the GlSSI trial is confirmation that the benefit obtained in the acute phase of acute myocardial infarction with a simple infusion of 1.5 million units of streptokinase persists for at least I year. The questions formulated in the first publication (2) appear to have been answered decisively from the data presented here. They are highly consistent with the hypothesis presented in the first report of GISSI ( I); namely, patients who survive the acute 36B .,. 415 ) 13.0 ( IJ6 of 893) 7.7 (322 of 4 , 197 ) 6.9 (300 of 4,3 (8) 18.1 (134 of 74 1) No statistically significant differences have been found in any of the reported subgroups. The differences that may be observed with respect to some variables (for example, Killip 4, ST t )are due to the small number of patients involved and are far from any statistical significance. Abbreviations as in Tables 1 and 2 . (0) As is dear from the 95o/r confidence intervals (Cl) cnlcularcd for the relative risk (RRI esnmutcs. a stati-ticully significanr difference in the rrcqucncy of events may be assumed to occur in the rates of reinlurction (both in the hospital phase and at 6 month follow-upI in luvur of the control (e) group. left ventricular failure (LVF) and pericarditis Iin hospital events. in favor of the streptokinase ISKl-treuted patients). CABO~coronary artery bypass graft: PTCA = percutaneous transluminal comnary angioplasty.
(hospital) phase of myocardial infarction have the same prognosis whether or not they were treated with a thrombolytic agent (1).
Effect on long-term clinical course and prognosis. The differences in the magnitude of the effects that were apparent during the hospital phase for the various subgroups (Table  2) do not herald a different long-term prognosis. It was the study's principal hypothesis that thrombolysis alone had to be shown to be effective in order to be generally applicable with no specific precautions, except those routinely applied in any coronary care unit. In addition to its public health implication, the affirmative answer provided by the study suggests that early reopening of the infarct-related coronary artery is decisive in determining outcome. Full anticoagulation, traditionally considered a mandatory component of thrombolytic therapy. was not the rule in the GISSI trial, and no differences were found between the reinfarction rates regardless of whether patients were treated with any of the drugs that are deemed to affect the thromhotic process (3). One finding deserves particular attention: there was a higher incidence of reocclusion in the treated versus the control groups both during the hospital phase and at the 6 month follow-up. However, reinfarction events did not appear to be prognostic of mortality when patients with and without such events were compared. No difference was found in the treated and control groups in any of the other clinical events determined at the 6 month follow-up (Table 4) .
Role of previous myocardial infarction. Possibly the most intriguing finding of the GISSI trial was the lack of an effect of streptokinase treatment in patients with a prior history of infarction. No satisfactory explanation is available, although the finding appears unlikely to he spurious or biased. Each patient's history, together with age, sex and time from onset of pain, was collected during the randomization telephone call made before the patient was assigned to one group. Further. the number of GISSI patients with a history of prior infarction is larger than the entire population of other trials (3). It will be interesting to assess the experience of the ISIS-2 trial (4) if the similar order of magnitude of a beneficial effect found in the preliminary analysis of one subgroup (patients treated <4 hours after the onset of pain) is indicative of that in a population similar to the one recruited into the GISSI trial.
Clinical implications. Unexpected findings of very large scale trials sometimes call for post hoc explanations of the results (5, 6) . Suggestions or recommendations drawn from subgroup analyses of smaller trials may be ingenious but are difficult to interpret (7, 8) .
The specific strength of the GISSI experience is that it provides a straightforward answer to the question of the effect of thrombolysis on a largely unselected population of patients with acute myocardial infarction that is representative of the potential recipients of this therapy. It will be interesting to determine how the early systematic application of more radical procedures such as coronary angioplasty and coronary bypass surgery modifies the natural course of postacute myocardial infarction found in streptokinase-treated patients in the GISSI trial.
